Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, Alan, Gray, Robert, Perry, Michael C., Brahmer, Julie, Schiller, Joan H., Dowlati, Afshin, Lilenbaum, Rogerio, Johnson, David H.·2006·New England Journal of Medicine

DOI 10.1056/nejmoa061884

Cited by (1,018)

Items 701–800 of 1,018

Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer
Thomas E. Stinchcombe, Mark A. Socinski · 2008 · The Oncologist
Bevacizumab: overview of the literature
Maria Ignez Braghiroli, Jorge Sabbaga, Paulo M. Hoff · 2012 · Expert Review of Anticancer Therapy
Genotype-driven therapies for non-small cell lung cancer: focus on EGFR , KRAS and ALK gene abnormalities
Elizabeth Mary Gaughan, Daniel Botelho Costa · 2011 · Therapeutic Advances in Medical Oncology
Improving Efficacy, Oral Bioavailability, and Delivery of Paclitaxel Using Protein-Grafted Solid Lipid Nanoparticles
Deep Pooja, Hitesh Kulhari, Madhusudana Kuncha, Shyam Sunder Rachamalla, David J. Adams, Vipul Bansal, Ramakrishna Sistla · 2016 · Molecular Pharmaceutics
Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry
Huizhi Sun, Danfang Zhang, Zhi Yao, Xian Lin, Jiameng Liu, Qiang Gu, Xueyi Dong, Fang Liu, Yi Wang, Nan Yao et al. · 2017 · Cancer Biology & Therapy
Lung cancer: Progress in diagnosis, staging and therapy
Stephen G Spiro, Nichole T. Tanner, Gerard A. Silvestri, Sam M. Janes, Eric Kian Saik Lim, Johan Vansteenkiste, Robert Pirker · 2009 · Respirology
Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
Sebastian Kobold, Susanna Hegewisch‐Becker, Karin Oechsle, Karin Jordan, Carsten Bokemeyer, Djordje Atanackovic · 2009 · The Oncologist
Crizotinib in the treatment of non-small-cell lung cancer
Patrick M. Forde, Charles M. Rudin · 2012 · Expert Opinion on Pharmacotherapy
Hypertension, Proteinuria, and Antagonism of Vascular Endothelial Growth Factor Signaling: Clinical Toxicity, Therapeutic Target, or Novel Biomarker?
Willem Jan van Heeckeren, José Ortiz, Matthew M. Cooney, Scot C. Remick · 2007 · Journal of Clinical Oncology
Personalized medicine for lung cancer: new challenges for pathology
Keith M. Kerr · 2011 · Histopathology
Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement
Joseph Patrick Erinjeri, Abigail Fong, Nancy E. Kemeny, Karen T. Brown, George I. Getrajdman, Stephen Barnett Solomon · 2010 · Cancer
Redefining the role of interferon in the treatment of malignant diseases
Sergio Bracarda A, Alexander M.M. Eggermont, Jan Samuelsson · 2009 · European Journal of Cancer
Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval
Alberto Felice Sobrero, Paolo Bruzzi · 2009 · Journal of Clinical Oncology
Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial
Jean-Louis Pujol, A. Lavolé, Élisabeth Quoix, Olivier Molinier, Pierre Jean Souquet, Fabrice Barlési, H. Le Caer, Denis Moro‐Sibilot, P. Fournel, J.P. Oster et al. · 2015 · Annals of Oncology
Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3, S100A2, S100A7, and Sox-2) for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung
Koji Tsuta, Yuko Tanabe, Akihiko Yoshida, Fumiaki Takahashi, Akiko Miyagi Maeshima, Hisao Asamura, Hitoshi Tsuda · 2011 · Journal of Thoracic Oncology
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non‐small cell lung cancer after two lines of chemotherapy
Ming Zhou, Xiaoyuan Chen, Hong Zhang, Lin Xia, Xin Tong, Limin Zou, Ruimin Hao, Jianhong Pan, Xiao Qing Zhao, Dongmei Chen et al. · 2019 · 癌症：英文版
Cancer stem cells and angiogenesis
Yue Zhao, Qi Bao, Andrea Renner, Peter Čamaj, Martin Eichhorn, Ivan Ischenko, Martin Kurt Angele, Axel Kleespies, Karl‐Walter Jauch, Christiane J. Bruns · 2011 · The International Journal of Developmental Biology
Antibody-based targeting of the tumor vasculature
Christoph Schliemann, Dario Neri · 2007 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
Joachim von Pawel, Jimmie Huling Harvey, David Robert Spigel, Mircea Dediu, Martin Reck, Cristina Ligia Cebotaru, Robin C. Humphreys, Matthew Gribbin, Norma Lynn Fox, D. Ross Camidge · 2014 · Clinical Lung Cancer
Tumoral Angiogenesis: Review of the Literature
Parham Khosravi Shahi, Israel Fernández Pineda · 2008 · Cancer Investigation
Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients
Ryota Masuda, Hiroshi Kijima, Naoko Imamura, Naohiro Aruga, Yusuke Nakamura, DAISUKE MASUDA, Haruka Takeichi, Nobusuke Kato, Tomoki Nakagawa, Makiko Rai Tanaka et al. · 2012 · Molecular Medicine Reports
Regional Variation in Spending and Survival for Older Adults With Advanced Cancer
Brooks, Gabriel A., Li, Ling, Sharma, Dhruv B., Weeks, Jane C., Hassett, Michael J., Yabroff, K. Robin, Schrag, Deborah · 2013 · JNCI: Journal of the National Cancer Institute
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials
Gideon Michael Blumenthal, Lijun Zhang, Hui Zhang, Dickran Gano Kazandjian, Sean Khozin, Shenghui W. Tang, Kirsten B. Goldberg, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur · 2017 · JAMA Oncology
Nanopaclitaxel Therapy: An Evidence Based Review on the Battle for Next-Generation Formulation Challenges
Harshita, Md. Abul Barkat, Sarwar Beg, Faheem Hyder Pottoo, Farhan Jalees Ahmad · 2019 · Nanomedicine
RNA-based therapies: A cog in the wheel of lung cancer defense
Parvez Κhan, Jawed Akhtar Siddiqui, Imayavaramban Lakshmanan, Apar Kishor Ganti, Ravi Salgia, Maneesh Jain, Surinder K. Batra, Mohd Wasim Nasser · 2021 · Molecular Cancer
Endothelial cell markers from clinician's perspective
Jelena Rakočević, Dejan N. Orlic, Olivera Mitrović Ajtić, Miloje V. Tomasevic, Milan R. Dobric, Natasa Zlatic, Dejan Milašinović, Goran R. Stankovic, Miodrag Ostojić, Milica Labudović‐Borović · 2017 · Experimental and Molecular Pathology
Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15
Rocca, Yamila Sol, Roberti, María Paula, Juliá, Estefanía Paula, Pampena, María Betina, Bruno, Luisina, Rivero, Sergio, Huertas, Eduardo, Sánchez Loria, Fernando, Pairola, Alejandro, Caignard, Anne et al. · 2016 · Frontiers in Immunology
Pulmonary toxicities from targeted therapies: a review
Nicholas A. Barber, Apar Kishor Ganti · 2011 · Targeted Oncology
Tumor angiogenesis and molecular targets for therapy
Yihai Cao · 2009 · Frontiers in bioscience
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
Martin Reck, Fabrice Barlési, Lucio Crinò, Claudia I. Henschke, Dolores Isla, Susanne Stiebeler, David Robert Spigel · 2011 · Annals of Oncology
Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients
Peter M. Ellis, Rolf Kaiser, Yihua Zhao, Peter Stopfer, Steve Gyorffy, Nasser H. Hanna · 2010 · Clinical Cancer Research
Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas
Yi Li, Shi-Yuan Fu, Lihui Wang, Fangyang Wang, Nannan Wang, Qi Cao, Yating Wang, Jingyu Yang, Chunfu Wu · 2015 · Cancer Letters
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials
Giandomenico Roviello, Thomas Bachelot, Clifford A. Hudis, Giuseppe Curigliano, Andrew R. Reynolds, Roberto Petrioli, Daniele Generali · 2017 · European Journal of Cancer
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
Kristen Ashley Marrone, Xian Chong Zhou, Patrick M. Forde, Michael Purtell, Julie Renee Brahmer, Christine L. Hann, Ronan Joseph Kelly, Barbara Coleman, Edward W. Gabrielson, Gary L. Rosner et al. · 2018 · The Oncologist
Positron Emission Tomography and Improved Survival in Patients With Lung Cancer The Will Rogers Phenomenon Revisited
Karen Giselle Chee · 2008 · Archives of Internal Medicine
A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer
Peter M. Ellis, Normand Blais, D. Soulieres, Diana N. Ionescu, Meenakshi Kashyap, Geoffrey Liu, B. Melosky, Tony Reiman, Phillip Romeo, Frances A. Shepherd et al. · 2011 · Journal of Thoracic Oncology
Angiogenesis in cancer - general pathways and their therapeutic implications
Ivanka Istalianova Dimova, Georgi Popivanov, Valentin Djonov · 2014 · PubMed
Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Adrian M. Jubb, Kathy D. Miller, Hope S. Rugo, Adrian Llewellyn Harris, Dafeng Chen, James D. Reimann, Melody Cobleigh, Maike Schmidt, Virginia K. Langmuir, Kenneth J. Hillan et al. · 2011 · Clinical Cancer Research
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
Bassel F. El‐Rayes, Mark M. Zalupski, Tanios Bekaii‐Saab, Lance K. Heilbrun, Nazik Hammad, Bhaumik B. Patel, Susan G. Urba, Anthony Frank Shields, Ulka N. Vaishampayan, S. Dawson et al. · 2010 · Annals of Oncology
MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma
Lipin Liu, Nan Bi, Lihong Wu, Xiao Ding, Yu Men, Wei Zhou, Lin Li, Weimin Zhang, Susheng Shi, Yongmei Song et al. · 2017 · Molecular Cancer
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
Xiaoyang Zhai, Jian Zhang, Yaru Tian, Ji Li, Jing Wang, Hongbo Guo, Hui Zhu · 2020 · Cancer Biology and Medicine
Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors
Ultan McDermott, Rachel Y. Ames, Anthony John Iafrate, Shyamala Maheswaran, Hannah Stubbs, Patricia Greninger, Kaitlin McCutcheon, Randy J. Milano, Angela Tam, Diana Wing Lee et al. · 2009 · Cancer Research
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli, Giuseppe Giaccone, Sarah Temin · 2010 · Journal of Oncology Practice
BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Bercin Kutluk Cenik, Katherine T. Ostapoff, David E. Gerber, Rolf A. Brekken · 2013 · Molecular Cancer Therapeutics
Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers
Kedan Lin, Bonnee Rubinfeld, Crystal Zhang, Ron Firestein, Eric B. Harstad, Leslie A. Roth, Siao Ping Tsai, Melissa M. Schutten, Keyang Xu, Maria L. Hristopoulos et al. · 2015 · Clinical Cancer Research
Practical Management of Bevacizumab-Related Toxicities in Glioblastoma
Alba Ariela Brandes, Marco Bartolotti, Alicia Tosoni, Rosalba Poggi, Enrico Franceschi · 2015 · The Oncologist
AJRCCM : 100-Y ear A nniversary . The Shifting Landscape for Lung Cancer: Past, Present, and Future
Anil Vachani, Lecia Van Dam Sequist, Avrum E. Spira · 2017 · American Journal of Respiratory and Critical Care Medicine
Drug radiotherapy combinations: Review of previous failures and reasons for future optimism
Geoff Stuart Higgins, Sean Michael O'Cathail, Ruth J. Muschel, William Gillies McKenna · 2015 · Cancer Treatment Reviews
Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis
Pei-Yuan Zuo, Xinglin Chen, Yuwei Liu, Chang-Liang Xiao, Chengyun Liu · 2014 · PLoS ONE
Randomized phase II / III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS ‐ PC Study
Hiroki Yamaue, Takuya Tsunoda, Masaji Tani, Motoki Miyazawa, Kenji Yamao, Nobumasa Mizuno, Takuji Okusaka, Hideki Ueno, Narikazu Boku, Akira Fukutomi et al. · 2015 · Cancer Science
Bevacizumab-Induced Hypertension
Kostas Syrigos, Eleni M. Karapanagiotou, Paraskevi Boura, Christian Manegold, Kevin Joseph Harrington · 2011 · BioDrugs
Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy
Suresh Senan, Egbert Frederik Smit · 2007 · The Oncologist
INTRAVITREAL BEVACIZUMAB DURING PREGNANCY
Ryan M. Tarantola, James C. Folk, H. Culver Boldt, Vinit B. Mahajan · 2010 · Retina
Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer
Rong Biaoxue, Yang Shuanying, Wei Li, Wei Zhang, Ming Zongjuan · 2012 · World Journal of Surgical Oncology
MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells
Lei Fan, Qiang Wu, Xiaojuan Xing, Yulong Wei, Zengwu Shao · 2012 · Acta Biochimica et Biophysica Sinica
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer
Katsuyuki Kiura, Kazuhiko Nakagawa, Tetsu Shinkai, Kenji Eguchi, Yuichiro Ohe, Nobuyuki Yamamoto, Masahiro Tsuboi, Soichiro Yokota, Takashi Seto, Haiyi Jiang et al. · 2008 · Journal of Thoracic Oncology
Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
Xiaofeng Hang, Wen Sheng Xu, Jun Xue Wang, Lei Wang, Hai Guang Xin, Rui Qi Zhang, Wu Ni · 2011 · European Journal of Clinical Pharmacology
Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors
F. Anthony Greco, Nicholas A. Pavlidis · 2009 · Seminars in Oncology
The emerging role of microRNAs in resistance to lung cancer treatments
Lauren MacDonagh, Steven G. Gray, Stephen P. Finn, Sinead D. Cuffe, Kenneth John O'Byrne, Martin P. Barr · 2014 · Cancer Treatment Reviews
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
Arjun Vasant Balar, Andrea Borghese Apolo, Irina Ostrovnaya, Svetlana Mironov, Alexia E. Iasonos, Alisa Trout, Ashley Marie Regazzi, Ilana Rebecca Garcia-Grossman, David James Gallagher, Matthew I. Milowsky et al. · 2013 · Journal of Clinical Oncology
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
Shintaro Kanda, K. Goto, H. Shiraishi, E. Kubo, Ayako Tanaka, Hirofumi Utsumi, Kuniko Sunami, Satoru Kitazono, Hidenori Mizugaki, Hidehito Horinouchi et al. · 2016 · Annals of Oncology
Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
Christopher Montemagno, Gilles Pagès · 2020 · Frontiers in Cell and Developmental Biology
Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer
Bilal Piperdi, Amartej Merla, Roman Perez-Soler · 2014 · Drugs
Antiangiogenic drugs in ovarian cancer
G. Kumaran, Gordon C. Jayson, Andrew R. Clamp · 2008 · British Journal of Cancer
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
Mark James McKeage, Martin Reck, Michael B. Jameson, Mark Andrew Rosenthal, David D. Gibbs, Paul N. Mainwaring, Lutz Freitag, Richard Sullivan, Joachim von Pawel · 2009 · Lung Cancer
Safety of anticoagulation use and bevacizumab in patients with glioma
Phioanh Leia Nghiemphu, Richard M. Green, Whitney B. Pope, Albert Lai, Timothy Francis Cloughesy · 2008 · Neuro-Oncology
Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis
Lima, André Bacellar Costa, Macedo, Ligia T., Sasse, André Deeke · 2011 · PLoS ONE
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
George R. Blumenschein, Fairooz F. Kabbinavar, Hari Menon, Tony S.K. Mok, John R. Stephenson, Joseph Thaddeus Beck, KC Lakshmaiah, Karen L. Reckamp, Y. Hei, Karolyn Kracht et al. · 2011 · Annals of Oncology
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
EC Martino, Gabriella Misso, Pierpaolo Pastina, Susan Costantini, Francesca Vanni, Claudia Gandolfo, Cirino Botta, Francesca Capone, Angela Lombardi, Luigi Pirtoli et al. · 2016 · Cell Death Discovery
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy
Erqi Liu Pollom, Lei Deng, Reetesh K. Pai, J. Martin Brown, Amato J. Giaccia, Billy W. Loo, David Benjamin Shultz, Quynh‐Thu Le, Albert C. Koong, Daniel Tandel Chang · 2015 · International Journal of Radiation Oncology*Biology*Physics
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
Manuela Schmidinger, Joaquim Bellmunt B · 2010 · Cancer Treatment Reviews
Bevacizumab for the Treatment of Glioblastoma
Miguel Gil‐Gil, Carlos Mesía, Montserrat Rey, Jordi Bruna · 2013 · Clinical Medicine Insights Oncology
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients
Cirino Botta, Vito Barbieri, Domenico Ciliberto, Antônio Rossi, Danilo Rocco, Raffaele Addeo, Nicoletta Staropoli, Pierpaolo Pastina, Giulia Marvaso, Ignazio Martellucci et al. · 2013 · Cancer Biology & Therapy
Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy
Andreas Pircher, Wolfgang Hilbe, Isabel Maria Heidegger, Joachim Drevs, André Tichelli, Michael Medinger · 2011 · International Journal of Molecular Sciences
Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms
Hrvoje Miletić, Simone P. Niclou, Mikael Johansson, Rolf Bjerkvig · 2009 · Expert Opinion on Therapeutic Targets
Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review
Dorothy M. K. Keefe, Joanne M. Bowen, Rachel J. Gibson, Thean Hsiang Tan, Meena Okera, Andrea M. Stringer · 2011 · The Oncologist
Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study
Neal Ready, Arkadiusz Zbigniew Dudek, Herbert Pang, Lydia D. Hodgson, Stephen L. Graziano, Mark R. Green, Everett E. Vokes · 2011 · Journal of Clinical Oncology
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
Melanie Mediavilla-Varela, Julio Castro, Alberto Chiappori, David R. Noyes, Dalia C. Hernandez, Bertrand Allard, John Stagg, Scott Joseph Antonia · 2017 · Neoplasia
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
Martin Reck, Thomas Wehler, Francesco Orlandi, Naoyuki Nogami, Carlo Barone, Denis Moro‐Sibilot, Mikhail I. Shtivelband, J.L. González-Larriba, Jeffrey M. Rothenstein, Martin Früh et al. · 2020 · Journal of Clinical Oncology
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma
Brian Z. Ring, Robert S. Seitz, Rodney A. Beck, William J. Shasteen, Alex Soltermann, Stefanie Arbogast, Francisco Robert, Marshall T. Schreeder, Douglas Teller Ross · 2009 · Modern Pathology
Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature
Valentina Fogal, Kazuki N. Sugahara, Erkki I. Ruoslahti, Sven Christian · 2009 · Angiogenesis
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
William P. Tew, Michael S. Gordon, John R. Murren, Jakob Dupont, S. Pezzulli, Carol A Aghajanian, Paul J. Sabbatini, David S. Mendelson, Lawrence Israel Schwartz, Scott N. Gettinger et al. · 2009 · Clinical Cancer Research
Angiogenesis: A Target in Solid Tumors, Also in Leukemia?
Thomas Schmidt, Peter Carmeliet · 2011 · Hematology
Endoglin for Targeted Cancer Treatment
Lee S. Rosen, Michael S. Gordon, Francisco Robert, Daniela Elena Matei · 2014 · Current Oncology Reports
Supramolecular polymeric chemotherapy based on cucurbit[7]uril-PEG copolymer
Hao Chen, Yueyue Chen, Han Wu, Jiang‐Fei Xu, Zhiwei Sun, Xi Zhang · 2018 · Biomaterials
Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer
Arik Bernard Schulze, Georg Evers, Andrea Kerkhoff, Michael Möhr, Christoph Schliemann, Wolfgang E. Berdel, Lars Henning Schmidt · 2019 · Cancers
Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience
Ngayu Thairu, Serafim Kiriakidis, Peter M Dawson, Ewa M Paleolog · 2011 · Angiogenesis
Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
Rob Eager, C.C. Cunningham, Neil N. Senzer, Donald Richards, Robert N. Raju, Barry Nelson Jones, Margaret J. Uprichard, John J. Nemunaitis · 2009 · Clinical Oncology
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
Adi F. Gazdar · 2010 · Cancer and Metastasis Reviews
Vorinostat increases carboplatin and paclitaxel activity in non‐small cell lung cancer cells
Taofeek Kunle Owonikoko, Suresh S. Ramalingam, Beatriz I. Kanterewicz, Trent E. Balius, Chandra Prakash Belani, Pamela A. Hershberger · 2009 · International Journal of Cancer
Therapeutic Antibodies Against Cancer
Mark J. Adler, Dimiter Stanchev Dimitrov · 2012 · Hematology/Oncology Clinics of North America
Phase 1 study of concurrent sunitinib and image‐guided radiotherapy followed by maintenance sunitinib for patients with oligometastases
Johnny Kao, Stuart H. Packer, Ha Linh Vu, Myron Schwartz, Max W. Sung, Richard G. Stock, Yeh‐Chi Lo, Delphine Huang, Shu‐Hsia Chen, Jamie A. Cesaretti · 2009 · Cancer
Translating genomic information into clinical medicine: Lung cancer as a paradigm
Mia Alyce Levy, Christine Marie Lovly, William J. Pao · 2012 · Genome Research
Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
Hooglugt, Aukie, van der Stoel, Miesje M., Boon, Reinier A., Huveneers, Stephan · 2021 · Frontiers in Oncology
A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung
Natasha B. Leighl, Luis Estuardo Raez, Benjamin Besse, Peter J. Rosen, Fabrice Barlési, Erminia Massarelli, Nashat Y. Gabrail, Lowell L. Hart, Kathy S. Albain, Lloyd Berkowitz et al. · 2010 · Journal of Thoracic Oncology
Circulating endothelial cells in oncology: pitfalls and promises
Michiel Hendrik Strijbos, Jan Willem Gratama, Jaco Kraan, C H Lamers, MA den Bakker, Stefan Sleijfer · 2008 · British Journal of Cancer
The role of combination chemo-immunotherapy in advanced non-small cell lung cancer
Danilo Rocco, Luigi Della Gravara, Ciro Battiloro, Cesare Gridelli · 2019 · Expert Review of Anticancer Therapy
Advances in the Treatment of Non–Small Cell Lung Cancer
Shetal Arvind Patel, Jared Weiss · 2020 · Clinics in Chest Medicine
Hypoxia-Inducible Factor (HIF)/Vascular Endothelial Growth Factor (VEGF) Signaling in the Retina
Toshihide Kurihara, Peter D. Westenskow, Martin Friedlander · 2014 · Advances in experimental medicine and biology
Advances in Treatment of Lung Cancer With Targeted Therapy
Philip T. Cagle, Lucian R. Chirieac · 2012 · Archives of Pathology & Laboratory Medicine